Sugi Predict

Sugi Predict / Compounds / SCHEMBL1146973

SCHEMBL1146973

SCHEMBL1146973

CC(C)(F)C[C@H](N)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.44
▸ GRIK1 P39086 5/20 0.42
▸ PTGS1 P23219 2/20 0.42
▸ SLC7A11 Q9UPY5 1/20 0.42
▸ NOS2 P35228 3/20 0.41
▸ NOS3 P29474 2/20 0.41
▸ NOS1 P29475 2/20 0.41
▸ SLC1A2 P43004 6/20 0.40
▸ SLC1A3 P43003 5/20 0.40
▸ SLC1A1 P43005 5/20 0.40
▸ GRIK2 Q13002 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ GRM8 O00222 1/20 0.39
▸ GRM6 O15303 1/20 0.39
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GSR P00390 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ GRM5 P41594 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL936382 1.00 SLC7A5 (0.44) SLC7A5GRIK1PTGS1SLC7A11NOS2
SCHEMBL19918392 1.00 SLC7A5 (0.44) SLC7A5GRIK1PTGS1SLC7A11NOS2
Hydrochloric Acid SCHEMBL18762600 0.98 SLC7A5 (0.43) SLC7A5GRIK1PTGS1SLC7A11NOS2
Sulfuric Acid SCHEMBL27041519 0.92 PMP22 (0.41) SLC7A5GRIK1PTGS1SLC7A11NOS2
Sulfuric Acid SCHEMBL27041515 0.92 PMP22 (0.41) SLC7A5GRIK1PTGS1SLC7A11NOS2
SCHEMBL890414 0.86 SLC7A5 (0.44) SLC7A5GRIK1PTGS1SLC7A11NOS2
SCHEMBL890415 0.86 SLC7A5 (0.44) SLC7A5GRIK1PTGS1SLC7A11NOS2
Bromide SCHEMBL4412737 0.84 SLC7A5 (0.43) SLC7A5GRIK1PTGS1SLC7A11NOS2
Hydrochloric Acid SCHEMBL4408945 0.84 SLC7A5 (0.43) SLC7A5GRIK1PTGS1SLC7A11NOS2
Hydrochloric Acid SCHEMBL3870800 0.84 SLC7A5 (0.43) SLC7A5GRIK1PTGS1SLC7A11NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116365044-A Electrolyte, secondary battery and electric equipment 欣旺达电动汽车电池有限公司 2023-06-30 — — CN claimed
EP-2167507-B1 Cysteine protease inhibitors MEDIVIR AB (SE) 2016-03-02 — — EP claimed
US-20120220602-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2012-08-30 — — US claimed
US-20110105524-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2011-05-05 — — US claimed
EP-2167507-A1 CYSTEINE PROTEASE INHIBITORS Medivir AB (SE) 2010-03-31 — — EP claimed
US-20090023748-A1 Cysteine Protease Inhibitors MEDIVIR AB (SE) 2009-01-22 — — US claimed
WO-2009000877-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-12-31 — — WO claimed
WO-2008114054-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-09-25 — — WO claimed
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARM INC (US) 2026-02-05 — — US disclosed
US-20260001914-A1 MACROCYCLIC PEPTIDES TARGETING KRAS MERCK SHARP & DOHME LLC (US) 2026-01-01 — — US disclosed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
EP-4640217-A1 ANTICANCER AGENT AGC INC. (JP) 2025-10-29 — — EP disclosed
US-20250312303-A1 ANTICANCER AGENT AGC Inc. (JP) 2025-10-09 — — US disclosed
WO-2009000877-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-12-31 — — WO disclosed
WO-2009000877-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-12-31 — — WO disclosed
US-7429674-B2 Process for preparing fluoroleucine alkyl esters MERCK & CO. INC.. (US) 2008-09-30 — — US disclosed
WO-2008114054-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-09-25 — — WO disclosed
WO-2008114054-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-09-25 — — WO disclosed
CN-1842515-A Cathepsin inhibitors MERCK FROSST CANADA INC (CA) 2006-10-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 SLC7A5 3072/4885GRIK1 3693/4885PTGS1 1498/4885
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF RICTOR, RPTOR, MTOR SLC7A5 374/4885GRIK1 940/4885PTGS1 3842/4885
US-20110105524-A1 CYSTEINE PROTEASE INHIBITORS CTSK, CTSL, CTSV SLC7A5 1718/4885GRIK1 1066/4885PTGS1 1183/4885
US-20090023748-A1 Cysteine Protease Inhibitors CTSK, CTSL, CTSV SLC7A5 1718/4885GRIK1 1066/4885PTGS1 1183/4885
US-20120220602-A1 CYSTEINE PROTEASE INHIBITORS CTSK, CTSL, CTSV SLC7A5 1718/4885GRIK1 1066/4885PTGS1 1183/4885
US-20260001914-A1 MACROCYCLIC PEPTIDES TARGETING KRAS KRAS, NRAS, HRAS SLC7A5 308/4885GRIK1 3259/4885PTGS1 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.